You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

Immune Checkpoint Inhibitors as First-Line Therapy for Metastatic Melanoma: Provider Update

  • Authors: Jaime E. Anderson, PharmD, BCOP, CMQ; Yana G. Najjar, MD; Kathleen M. Madden, RN, MSN, FNP-BC, AOCNP, APHN- BC
  • CME / CE Released: 11/15/2022
  • Valid for credit through: 5/15/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    Nurses - 1.50 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for oncologists, oncology nurses and nurse practitioners, and oncology pharmacists.

To provide education on the use of ICIs as first-line therapy for metastatic melanoma including monotherapy and combination regimens, emerging therapies, and adverse drug effects, which will serve to optimize patient outcomes and quality of life.

Upon completion of this activity, participants will:

  1. Identify immunotherapy agents and regimens approved and optimal for first-line treatment of metastatic melanoma
  2. Indicate factors that impact selection of first-line agents and regimens
  3. Explain the basis of non-response to immunotherapy agents and regimens in use for metastatic melanoma and rational strategies to overcome this non-response
  4. Formulate approaches for identifying and mitigating toxicities associated with immunotherapy to optimize treatment outcomes and patient safety


Disclosures

Disclosure of Unlabeled Use and Disclaimer:

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine (PIM), or Bristol Myers Squibb. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.


Faculty

  • Jaime E. Anderson, PharmD, BCOP, CMQ

    Manager, Clinical Pharmacy Services
    Clinical Pharmacy Specialist
    Melanoma Medical Oncology
    Division of Pharmacy
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Jaime E. Anderson, PharmD, BCOP, CMQ, has no relevant financial relationships.

  • Yana G. Najjar, MD

    Assistant Professor of Medicine
    Research Physician—Melanoma
    Hematology-Oncology, Department of Medicine
    UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania

    Disclosures

    Yana G. Najjar, MD, has the following relevant financial relationships:
    Consultant or advisor for: Array Biopharma; Intervenn Bio; Merck & Co.; Novartis
    Speaker or member of speakers bureau for: Immunocore; Pfizer
    Contracted researcher for: Bristol Myers Squibb; Merck & Co.; Pfizer

  • Kathleen M. Madden, RN, MSN, FNP-BC, AOCNP, APHN-BC

    Family Nurse Practitioner
    Melanoma/Sarcoma Medical Oncology Group
    APN Manager
    Melanoma/ Cutaneous Oncology & Phase 1 Research
    New York University Langone
    Perlmutter Cancer Center
    New York, New York

    Disclosures

    Kathleen M. Madden, RN, MSN, FNP-BC, AOCNP, APHN-BC, has the following relevant financial relationships:
    Consultant or advisor for: Novartis

The clinical reviewer, Megan May, PharmD, BCOP has no relevant financial relationships.

Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

The PIM planners and others have no relevant financial relationships.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
 

All relevant financial relationships have been mitigated.


Accreditation Statements


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    For questions regarding the certification of this activity, contact [email protected].

    Contact This Provider

    For Nurses

  • The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

    Published: October 20, 2022

    Expires: April 20, 2023

    Type of Activity: Application

    Media: Internet

    Fee Information: There is no fee for this educational activity.

    Estimated time to complete activity: 90 minutes

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of  70%  on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

Immune Checkpoint Inhibitors as First-Line Therapy for Metastatic Melanoma: Provider Update

Authors: Jaime E. Anderson, PharmD, BCOP, CMQ; Yana G. Najjar, MD; Kathleen M. Madden, RN, MSN, FNP-BC, AOCNP, APHN- BCFaculty and Disclosures

CME / CE Released: 11/15/2022

Valid for credit through: 5/15/2023

processing....

Learning Feedback Questions

Before you begin, please take this brief survey.